SLBST Pharma’s Post

How is biotech pioneering new patient options for endometriosis? 🚀 Affecting around 190 million women and girls, endometriosis is a condition that has been rather difficult to treat with no cures to date. 📅 It is caused by the growth of tissue outside the uterus, leading to debilitating pelvic pain during sex and heavy periods. With some clinical trials showing promise and with the discovery of new drug targets, there is hope for better endometriosis care. 💊 Read our latest article to find out about some of the recent advancements in endometriosis research! 👇 https://lnkd.in/dXAXCu7w #endometriosis #biotechinnovation #womenshealth #clinicaltrials #medicalresearch #healthcareinnovation #biotechnews Bruce Nicholson | Hera Biotech | The University of Edinburgh | TiumBio | Serac Healthcare | Western Sydney University | FimmCyte | Celmatix

🌐 Exciting News in Healthcare! The Global Uterine Fibroid Diagnostics and Therapeutics Market is projected to soar to US$832M at a robust CAGR of 10.6% by 2027. 🚀 To Know More: https://lnkd.in/dna5e2uJ Curious about the Research Methodology? 🧐 Grab your insights with a Free Sample Report. Explore the profound impact of COVID-19 on key players' revenue and the market's short-term and long-term outlook. #Uterine fibroids, common during pregnancy, are non-cancerous #tumors posing varied sizes. The market's #growth is fueled by increased #awareness, advanced #diagnostic techniques like MRI scanners, and #evolving treatments. 💡 What's driving this surge? ✅ Rise in prevalence due to inheritance ✅ Growing therapies to cure uterine fibroids ✅ Increasing healthcare expenditure ✅ Surge in demand for fibroid drugs 🌍 Regional Insights: The Asia-Pacific region leads the charge with a burgeoning demand for Uterine Fibroid Diagnostics and Therapeutics. Lifestyle changes, healthcare investments, and a rising number of women of reproductive age are driving growth. 🔍 Market Segmentation: Dive into the intricacies of #fibroid types, #diagnostic tools (MRI, CT, Ultrasounds), and #diverse treatments (Embolization, Focused Ultrasound, Myolysis, Ablation, Hysterectomy, #Myomectomy). 📊 Comprehensive Analysis: The report delves deep into market #dynamics, key player strategies, and the competitive landscape. Discover the industry's past, present, and future with a focus on market leaders, followers, and new entrants. 🚀 Ready to make informed decisions? This report serves as your investor's guide in navigating the Global Uterine Fibroid Diagnostics and Therapeutics Market. Inquire now! 🌟 #HealthcareInnovation #MarketInsights #UterineFibroids #MedicalResearch 🌐💊

Pretty interesting innovative announcement from Roche Diagnostics, which has received approval for a new way to diagnose Polycystic Ovary Syndrome (PCOS) PCOS. PCOS is a common condition in women that can affect their reproductive system, metabolism, and mental well-being. The new method involves a blood test called Elecsys Anti-Müllerian Hormone (AMH) which is a huge development because it provides a quicker, easier way to diagnose PCOS for women with less discomfort. Previous methods, like transvaginal ultrasounds, can be uncomfortable. This is significantly different than the in vitro diagnostic test offered by Roche which is helping to change the landscape to provide further equity and access for the women's health landscape. https://lnkd.in/dNawPKbM

US-based #biotech company Qvin has developed the first and only healthcare service that collects menstrual blood samples as an alternative to traditionally collected venous blood draws for biomarker indicators. Congratulations to Qvin Co-founder Sara Naseri & Team! FDA clearance, Naseri said, would make it possible for the millions of women in America who live with diabetes to receive monitoring of A1c, using laboratory tests performed on the Q-Pad. The move is hoped to be an opportunity for testing important biomarkers for the more than 80 million people who menstruate in the US. The Qvin A1c Q-Pad Test Kit measures the average blood sugar over a three-month period, by testing the A1c biomarker for people with diabetes. Each pad includes a removable strip. Once the pad has sufficiently collected a menstrual sample, the removed collection strip is sent to a lab for clinical testing. Users then receive their results via an app. In Asia, keep an eye on FemTech Association Asia member WomenX Biotech Limited, whose menstrual pads collect period blood for disease detection. The company also supports non-invasive research on #cervicalcancer and outreach to female students in low-income households. 🖋 Sorina Mihaila 📷 Femtech World https://lnkd.in/erPdudHa #femtechassociationasia #femtech #fda #menstrualhealth #diagnostics #indicators #healthtech #healthcare #womenshealth #innovation

Oxytocin: “The Love Hormone” (Affectionately Called) Oxytocin is a hormone and a neurotransmitter that affects many aspects of reproduction, bonding, and behavior. Richie’s Specialty Pharmacy is evaluating Oxytocin and the potential viability of delivering the drug sublingually (under the tongue) in a compounded form using SubMagna™ HMW as the carrying vehicle. Once finalized, and should it be deemed viable, it is our intent to share that information widely with pharmacies worldwide. The website www.sub-oxytocin.com has already been acquired and information found, should it be pertinent and viable, will be placed there. In the meantime, information regarding this drug can be found at the following two websites: https://lnkd.in/gkViwkzA https://lnkd.in/eyKCBFrg

#breakthrough #pharmanews #womenhealth Qvin™ Introduces Q-Pad™: Transforming Women's Health with FDA-Cleared Lab Testing using Menstrual Blood Qvin, a biotechnology research company, has developed the Q-Pad, a healthcare service that collects menstrual blood samples as an alternative to traditional blood draws. The Q-Pad recently received FDA clearance to measure A1c, an important biomarker for diabetes. It can also test for #diabetes, #anaemia, #fertility #perimenopause, #endometriosis, and #thyroidhealth With the first-ever FDA-cleared menstrual blood health test, Qvin is paving the way to important new opportunities for women's health and this is just the beginning! #opportunities #healthcareinnovation

Check out the latest report from IMIR Market Research Pvt. Ltd.  on the 𝗪𝗼𝗺𝗲𝗻'𝘀 𝗛𝗲𝗮𝗹𝘁𝗵 𝗗𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰𝘀 𝗠𝗮𝗿𝗸𝗲𝘁 Outlook and Geography Forecast till 2028 Don't miss out on this opportunity to stay informed about the latest trends in the industry. Women's Health Diagnostics Market Size, Share & Trends Analysis Report By Device Type (Biopsy Devices, Imaging & Monitoring Systems [Ultrasound Devices, Mammography Systems, MRI Systems, Others], Kits & Reagents, Consumable & Accessories), By Test Type (Brest cancer testing, Cervical cancer testing, Prenatal genetic screening & carrier testing, Pregnancy testing, Fertility & ovulation testing, Infection disease testing, Others), By End User (Hospital, Diagnostic laboratories & imaging centers, Specialty clinics, Others), Covid-19's Impacts, Global Economy Insights, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2023 - 2031 📚 𝐆𝐞𝐭 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐚𝐭 𝐝𝐢𝐬𝐜𝐨𝐮𝐧𝐭𝐞𝐝 𝐩𝐫𝐢𝐜𝐞:👇 https://lnkd.in/dBqtrdph 📚𝐓𝐨𝐩 𝐌𝐨𝐫𝐞 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐀𝐫𝐞::👇 Abbott AccuBioTech Co., Ltd. Agilent Technologies. Alere Inc.. BD Bio-Rad Laboratories. bioMérieux Cardinal Health. Carestream Chembio Diagnostics, Inc. Cook Medical. Danaher Corporation. Dialab GmbH EKF DIAGNOSTICS HOLDINGS PLC Exact Sciences. F. Hoffmann-La Roche Ltd. FUJIFILM Corporation. GE HealthCare Guided Therapeutics, Inc. Hologic, Inc.. Illumina. Invitae. MANKIND PHARMA LTD MedGyn Products, Inc. Myriad Genetics. Natera. Neurológica Nova Biomedical OSI Systems. Osteometer MediTech, Inc. PerkinElmer. Procter & Gamble. QIAGEN Quest Diagnostics QuidelOrtho. SEKISUI Diagnostics Siemens AG SuperSonic Imagine #womenhealth #health #women #healthylifestyle #fitness #womenempowerment #wellness #womenhealthcare #pcos #fertility #weightloss #healthyfood #selfcare #love #menhealth #motivation #healthy #pregnancy #healthcare #healthyliving #menstrualcramps #endometriosis #vaginalhealth #yonisteam #periodproblems #womenshealth #womensupportingwomen #menstruation #infertility #fibroid

Women in Healthcare: Clinical studies and expertise Our very first clinical trial in 1999 was in postmenopausal women - 25 years later, gynecology is still one of our core competencies and our female colleagues are still at the forefront of our business. 💡 The 1999 study was designed to demonstrate the bioavailability and pharmacodynamics of a grandfather drug. A drug that had been used in females for decades but was still poorly understood. 🤝 From 2011 onwards, dinox GmbH has been our strong partner for clinical trials in gynecology. 👩💼 Experience meets expertise: Also on the other side of the clinical trials, our women are strong in coordinating, monitoring, reporting, submitting and everything else it takes to run successful studies.  🎉Happy Women's Day!

It's Endometriosis Awareness Month - an opportunity to increase understanding and show support for the 176+ million people worldwide affected by the debilitating condition. Endometriosis occurs when tissues similar to the lining of the uterus grow outside of it, known as endometrial lesions. These lesions cause severe pain and can impact fertility. Despite affecting up to 1 in 10 women, the average time to diagnosis from the onset of symptoms is 8 years. Thankfully there has been some promising R&D happening in the space over the past year, here's a two that caught our eye: 1. Using MRI to non-invasively spot endometriosis: The lack of validated biomarkers for endometriosis had previously made it hard to develop targets for imaging and diagnosis. But in August 2023, a team of researchers from China made a breakthrough. They developed a contrast agent modified with a drug called bevacizumab. The drug targets a protein called Vascular Endothelial Growth Factor (VEGF), which is often present in people with endometriosis. This is a hugely promising development in the non-invasive diagnosis of the condition. Read the full study: https://lnkd.in/ggKUmA-v 2. Endometrial lesion detection: In January last year, researchers published a paper about a new, easier way to spot endometrial lesions using quantitative radiomics. The results showed that the radiomics model they developed could accurately classify the lesions as benign or malignant. This suggests that using MRI radiomics alongside clinical information could help doctors diagnose endometrial lesions more accurately. Learn more: https://lnkd.in/g4XjPpZv #EndometriosisAwarenessMonth #Endometriosis #MedicalImaging

Promising Advances in Endometriosis Treatment! 🚀 Early research hints at a groundbreaking solution on the horizon. Dichloroacetate (DCA), a drug used in metabolic diseases, shows potential in breaking down cells responsible for endometriosis, a prevalent and debilitating condition affecting 1 in 10 women worldwide. Endometriosis takes a toll on women's health, causing severe pain, fatigue, and fertility challenges. With no current cure, the societal burden is substantial, reaching an estimated £8.2 billion annually in the UK and $119 billion in the United States alone. 🌟 This spring, Professor Andrew Horne, (PhD, FRCOG, FRCP Edin, FRCSEd, FRSE), Co-Director of EXPPECT at the The University of Edinburgh advances DCA's clinical trial into its second phase. The goal? NHS approval as a treatment within the next five years. 🔬 The science behind it is intriguing – targeting lactate production, a key factor in endometriosis growth. Positive outcomes from the trial's initial phase are sparking optimism. The developments will be interesting, as will be the impact on the landscape of women's pelvic health and health in general. #HealthTech #InvestInHealth #EndometriosisInnovation #WomenHealth #Pelvichealth https://lnkd.in/ebUnHRdJ